140 related articles for article (PubMed ID: 37455385)
1. Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT).
Neyaz A; Crotty R; Rickelt S; Pankaj A; Stojanova M; Michelakos TP; Sekigami Y; Kontos F; Parrack PH; Patil DT; Heaphy CM; Ferrone CR; Deshpande V
Histopathology; 2023 Oct; 83(4):546-558. PubMed ID: 37455385
[TBL] [Abstract][Full Text] [Related]
2. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
[TBL] [Abstract][Full Text] [Related]
3. Assessment of ARX expression, a novel biomarker for metastatic risk in pancreatic neuroendocrine tumors, in endoscopic ultrasound fine-needle aspiration.
Hackeng WM; Morsink FHM; Moons LMG; Heaphy CM; Offerhaus GJA; Dreijerink KMA; Brosens LAA
Diagn Cytopathol; 2020 Apr; 48(4):308-315. PubMed ID: 31846235
[TBL] [Abstract][Full Text] [Related]
4. Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas.
Hackeng WM; Schelhaas W; Morsink FHM; Heidsma CM; van Eeden S; Valk GD; Vriens MR; Heaphy CM; Nieveen van Dijkum EJM; Offerhaus GJA; Dreijerink KMA; Brosens LAA
Endocr Pathol; 2020 Jun; 31(2):108-118. PubMed ID: 32103422
[TBL] [Abstract][Full Text] [Related]
5. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).
Heaphy CM; Singhi AD
Hum Pathol; 2023 Feb; 132():1-11. PubMed ID: 36702689
[TBL] [Abstract][Full Text] [Related]
6. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
[No Abstract] [Full Text] [Related]
7. Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours.
Kim JY; Brosnan-Cashman JA; Kim J; An S; Lee KB; Kim H; Park DY; Jang KT; Oh YH; Hruban RH; Heaphy CM; Hong SM
Pathology; 2020 Apr; 52(3):336-347. PubMed ID: 32111396
[TBL] [Abstract][Full Text] [Related]
8. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.
Heaphy CM; Singhi AD
Hum Pathol; 2022 Nov; 129():11-20. PubMed ID: 35872157
[TBL] [Abstract][Full Text] [Related]
10. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.
Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF
Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669
[TBL] [Abstract][Full Text] [Related]
11. Alternative Lengthening of Telomeres Phenotype Predicts Progression Risk in Noninsulinomas in a Chinese Cohort.
Ban X; Mo S; Lu Z; Jia C; Shao H; Yan J; Chang X; Mao X; Wu Y; Zhang Y; Fan X; Yu S; Chen J
Neuroendocrinology; 2022; 112(5):510-522. PubMed ID: 34348341
[TBL] [Abstract][Full Text] [Related]
12. Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases.
Dogeas E; Karagkounis G; Heaphy CM; Hirose K; Pawlik TM; Wolfgang CL; Meeker A; Hruban RH; Cameron JL; Choti MA
J Am Coll Surg; 2014 Apr; 218(4):628-35. PubMed ID: 24655849
[TBL] [Abstract][Full Text] [Related]
13. Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1.
Hackeng WM; van Beek DJ; Kok ASM; van Emst M; Morsink FHM; van Treijen MJC; Borel Rinkes IHM; Dreijerink KMA; Offerhaus GJA; Valk GD; Vriens MR; Brosens LAA
Am J Surg Pathol; 2022 Feb; 46(2):159-168. PubMed ID: 34560682
[TBL] [Abstract][Full Text] [Related]
14. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
[TBL] [Abstract][Full Text] [Related]
15. CT Radiogenomic Characterization of the Alternative Lengthening of Telomeres Phenotype in Pancreatic Neuroendocrine Tumors.
McGovern JM; Singhi AD; Borhani AA; Furlan A; McGrath KM; Zeh HJ; Bahary N; Dasyam AK
AJR Am J Roentgenol; 2018 Nov; 211(5):1020-1025. PubMed ID: 30160983
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors.
Hackeng WM; Assi HA; Westerbeke FHM; Brosens LAA; Heaphy CM
Surg Pathol Clin; 2022 Sep; 15(3):541-554. PubMed ID: 36049835
[TBL] [Abstract][Full Text] [Related]
18. Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases.
Pea A; Yu J; Marchionni L; Noe M; Luchini C; Pulvirenti A; de Wilde RF; Brosens LA; Rezaee N; Javed A; Chianchiano P; Gobbo S; Regi P; Salvia R; Bassi C; He J; Weiss MJ; Cameron JL; Offerhaus GJA; Hruban RH; Lawlor RT; Scarpa A; Heaphy CM; Wood LD; Wolfgang CL
Ann Surg; 2020 Mar; 271(3):566-573. PubMed ID: 30339629
[TBL] [Abstract][Full Text] [Related]
19. Insights into Epigenetic Changes Related to Genetic Variants and Cells-of-Origin of Pancreatic Neuroendocrine Tumors: An Algorithm for Practical Workup.
Ciobanu OA; Martin SC; Herlea V; Fica S
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139607
[TBL] [Abstract][Full Text] [Related]
20. Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.
Alzoubi H; Minasi S; Gianno F; Antonelli M; Belardinilli F; Giangaspero F; Jaffrain-Rea ML; Buttarelli FR
Endocr Pathol; 2022 Dec; 33(4):494-505. PubMed ID: 34993885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
